Abstract

Deep machine learning is expanding the conceptual framework and capacity of computational compound design, enabling new applications through generative modeling. We have explored the systematic design of covalent protein kinase inhibitors by learning from kinome-relevant chemical space, followed by focusing on an exemplary kinase of interest. Covalent inhibitors experience a renaissance in drug discovery, especially for targeting protein kinases. However, computational design of this class of inhibitors has thus far only been little investigated. To this end, we have devised a computational approach combining fragment-based design and deep generative modeling augmented by three-dimensional pharmacophore screening. This approach is thought to be particularly relevant for medicinal chemistry applications because it combines knowledge-based elements with deep learning and is chemically intuitive. As an exemplary application, we report for Bruton’s tyrosine kinase (BTK), a major drug target for the treatment of inflammatory diseases and leukemia, the generation of novel candidate inhibitors with a specific chemically reactive group for covalent modification, requiring only little target-specific compound information to guide the design efforts. Newly generated compounds include known inhibitors and characteristic substructures and many novel candidates, thus lending credence to the computational approach, which is readily applicable to other targets.

Highlights

  • Increasing interest in artificial intelligence methods is impacting computer-aided drug design and widening its scope [1]

  • We have addressed the question of whether novel covalent inhibitors of Bruton’s tyrosine kinase (BTK) could be designed via deep generative modeling by focusing on ibrutinib as a template and its interactions with BTK

  • BTK contains a free cysteine in the F2 subsite in the front region of the ATP cofactor binding site, the location of which is shared by a total of human kinases [8]

Read more

Summary

Introduction

Increasing interest in artificial intelligence methods is impacting computer-aided drug design and widening its scope [1]. Generative modeling is among the new approaches enabled through the application of deep neural network architectures [1,2,3,4]. It aims to produce novel chemical entities through deep learning from existing chemical matter, either by generally expanding biologically relevant chemical space through the generation of novel virtual libraries or by focusing on compounds with specific biological activities [2,3,4]. Generative modeling is intensely investigated at present, reports of practical applications impacting medicinal chemistry are still rare [1] This is typically the case for newly introduced (computational and experimental) methodologies, which will require time until they mature and measurably contribute to the practical drug design and medicinal chemistry programs.

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call